← All trials
NCT05657860
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 17, 2020
- Primary completion
- Feb 16, 2023
- Completion date
- Feb 16, 2023
- First posted
- Dec 20, 2022
- Last posted
- Dec 22, 2022
- Enrollment
- 33
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Maimonides Medical CenterLead sponsor
- Maimonides Medical CenterOverall official - principal investigator
Drugs studied
Indications studied
- Congenital Abnormalities
- Abnormalities, Multiple
- Aggression
- Antihypertensive Agents
- Behavioral Symptoms
- Dermatology
- Intellectual Disability
- Nervous System Diseases
- Neurologic Manifestations
- Nutrition Disorders
- Obesity
- Pathologic Processes
- Prader-Willi Syndrome
- Self-Injurious Behavior
- Neurotransmitter Agents
- Neurobehavioral Manifestations
- Chromosome Disorders
- Genetic Diseases, Inborn
- Overnutrition
- Molecular Mechanisms of Pharmacological Action
- Physiological Effects of Drugs
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.